Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 20/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 16/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15954623 | 0.88 | PDE4B (1.00) | PDE4BPDE4DTMEM97 | |
| SCHEMBL15954233 | 0.88 | PDE4B (1.00) | PDE4BPDE4DTMEM97 | |
| SCHEMBL27269818 | 0.83 | PDE4B (0.80) | PDE4BPDE4D | |
| SCHEMBL15954216 | 0.80 | PDE4B (1.00) | PDE4BPDE4D | |
| SCHEMBL15953669 | 0.79 | PDE4B (1.00) | PDE4BPDE4D | |
| SCHEMBL15954659 | 0.79 | PDE4B (1.00) | PDE4BPDE4D | |
| SCHEMBL15953909 | 0.76 | PDE4B (0.82) | PDE4BPDE4DTMEM97 | |
| SCHEMBL2778631 | 0.74 | PDE4B (0.60) | PDE4BPDE4D | |
| SCHEMBL15953263 | 0.73 | PDE4B (1.00) | PDE4BPDE4DTMEM97 | |
| SCHEMBL15954084 | 0.73 | PDE4B (1.00) | PDE4BPDE4DTMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815832-B2 | Azabenzimidazole compounds | PFIZER INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815832-B2 | Azabenzimidazole compounds | PFIZER INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815832-B2 | Azabenzimidazole compounds | PFIZER INC. (US) | 2017-11-14 | — | — | US | disclosed |
| EP-2958915-B1 | AZABENZIMIDAZOLE COMPOUNDS AS INHIBITORS OF PDE4 ISOZYMES FOR THE TREATMENT OF CNS AND OTHER DISORDERS | PFIZER (US) | 2017-07-05 | — | — | EP | disclosed |
| EP-2958915-B1 | AZABENZIMIDAZOLE COMPOUNDS AS INHIBITORS OF PDE4 ISOZYMES FOR THE TREATMENT OF CNS AND OTHER DISORDERS | PFIZER (US) | 2017-07-05 | — | — | EP | disclosed |
| US-20150322065-A1 | Azabenzimidazole Compounds | PFIZER (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150322065-A1 | Azabenzimidazole Compounds | PFIZER (US) | 2015-11-12 | — | — | US | disclosed |
| US-9120788-B2 | Azabenzimidazole compounds | PFIZER INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120788-B2 | Azabenzimidazole compounds | PFIZER INC. (US) | 2015-09-01 | — | — | US | disclosed |
| WO-2014128585-A1 | AZABENZIMIDAZOLE COMPOUNDS AS INHIBITORS OF PDE4 ISOZYMES FOR THE TREATMENT OF CNS AND OTHER DISORDERS | PFIZER INC. (US) | 2014-08-28 | — | — | WO | disclosed |
| US-20140235612-A1 | Azabenzimidazole Compounds | PFIZER (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235612-A1 | Azabenzimidazole Compounds | PFIZER (US) | 2014-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322065-A1 | Azabenzimidazole Compounds | AZI2, HDAC6, ABL1 | PDE4B 473/4885PDE4D 613/4885TMEM97 1962/4885 |
| US-20140235612-A1 | Azabenzimidazole Compounds | AZI2, HDAC6, ABL1 | PDE4B 473/4885PDE4D 613/4885TMEM97 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.